Table 1 Subject characteristics
From: Plasma amyloid-β oligomerization assay as a pre-screening test for amyloid status
| Total cohort | Sample storage period (≤ 4 years) | Sample storage period (> 4 years) | ||||
|---|---|---|---|---|---|---|
| PET-based amyloid status (n = 399) | PET-based amyloid status (n = 207) | PET-based amyloid status (n = 192) | ||||
| Normal (n = 193) | Abnormal (n = 206) | Normal (n = 139) | Abnormal (n = 68) | Normal (n = 54) | Abnormal (n = 138) | |
| Age, year | 64.4 (6.5) | 63.2 (6.6) | 64.6 (6.2) | 63.2 (6.5) | 64.0 (7.3) | 63.2 (6.7) |
| Female sex, n % | 75 (39) | 101 (49)* | 54 (39) | 34 (50) | 21 (39) | 67 (49) |
| MMSE (n = 393) | 26 (4) | 22 (5)*** | 27 (3.9) | 22 (4.7)*** | 25 (3.7) | 22 (4.6)*** |
| Education, year (n = 334) | 10.7 (2.9) | 11.4 (2.9)* | 10.5 (2.9) | 11.0 (2.6) | 10.9 (3.0) | 11.7 (3.0) |
| Diagnosis | ||||||
| CNb/MCI/AD/ | 70/15/11/ | 4/27/153/*** | 63/4/6/ | 2/10/44/*** | 7/11/5/ | 2/17/109/*** |
| Non-AD/Other | 49/48 | 9/13 | 30/36 | 3/9 | 19/12 | 6/4 |
| APOE ε4 carrier (n = 389) | 59 (30%) | 140 (70%)*** | 42 (31%) | 46 (69%)*** | 17 (32%) | 94 (72%)*** |
| CSF aβ42 (pg/ml) | ||||||
| Innotest (n = 268) | 1033 (246) | 629 (131)*** | 1036 (284) | 610 (182)*** | 1027 (184) | 638 (102)*** |
| Euroimmun (n = 60) | 999 (309) | NA | 999 (309) | NA | 999 (309) | NA |
| Plasma MDS-OAβ assaya | 0.80 (0.33) | 0.97 (0.35)*** | 0.76 (0.32) | 1.03 (0.28)*** | 0.89 (0.35) | 0.95 (0.37) |